Status:
COMPLETED
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Candidiasis
Candidemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
Detailed Description
The purpose of the study is to determine the efficacy and safety of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia. The maximum length o...
Eligibility Criteria
Inclusion
- Patients must have candidemia or invasive candidiasis.
Exclusion
- Patients who have received an echinocandin within one month prior to study entry.
- Patients who have received more than two days of prior systemic antifungal therapy for the current infection.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
611 Patients enrolled
Trial Details
Trial ID
NCT00105144
Start Date
September 1 2004
End Date
April 1 2006
Last Update
September 18 2014
Active Locations (167)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35294
2
Little Rock, Arkansas, United States, 72205
3
Los Angeles, California, United States, 90033
4
Los Angeles, California, United States, 90095